# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of...
PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.19) per share. This is a 26.67 percent decrease over losses of $...
VE202 was well tolerated, with no reports of treatment-related serious adverse eventsAdditional analyses from COLLECTiVE202 to ...
Former Teva North America CEO Sven Dethlefs, PhD, to lead CeleaPureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech...